Skip to main content

Table 1 Clinical characteristics and data of AIDS patient with CM in the study cohort

From: The clinical characteristics and outcome of cryptococcal meningitis with AIDS in a tertiary hospital in China: an observational cohort study

Variables Total(n = 128) Effective cohort(n = 101) Ineffective cohort(n = 27) Statistic P-value
age 37.5 (30.25, 46.75) 36 (30, 44.5) 42.3 ± 13.5 −1.981 0.048
Sex (cases)
 Male 113 (88.3%) 92 (91.1%) 21 (77.8%) −1.903 0.057
 Female 15 (11.7) 9 (8.9%) 6 (22.2%)
Complications (cases)
 Tuberculous meningitis 14 (10.9%) 9 (8.9) 5 (18.5%) −1.415 0.157
 Purulent meningitis 9 (7%) 6 (5.9%) 3 (11.1%) −0.930 0.352
 Cryptococcal pneumonia 31 (24.2%) 26 (25.7%) 5 (18.5%) −0.775 0.438
 Epilepsy 11 (8.6%) 10 (9.9%) 1 (3.7%) −1.017 0.309
 Optic papillary edema 6 (4.7%) 5 (5%) 1 (3.7%) −0.271 0.786
 Deafness 6 (4.7) 6 (5.9%) 0 (0%) −1.292 0.196
 Hydrocephalus 3 (2.3%) 2 (2%) 1 (3.7%) −0.524 0.600
 Cerebral hernia 4 (3.1%) 2 (2%) 2 (7.4%) −1.434 0.152
 Cerebral infarction 8 (6.3%) 4 (4%) 4 (14.8%) −2.062 0.039
Signs and symptoms (cases)
 Fever 109 (85.2%) 89 (88.1%) 20 (74.1%) −1.816 0.069
 Sweat 29 (22.7%) 24 (23.8%) 5 (18.5%) −0.576 0.565
 Headache 119 (93%) 93 (92.1%) 26 (96.3%) −0.758 0.448
 Nausea and vomiting 95 (74.2%) 76 (75.2%) 19 (70.4%) −0.513 0.608
 Consciousness disorder 52 (40.6%) 36 (35.6%) 16 (59.3%) −2.211 0.027
 Eye disease 41 (32%) 31 (30.7%) 10 (37%) −0.625 0.532
 Cranial nerve injury 38 (29.7%) 27 (26.7%) 11 (40.7%) −1.410 0.159
 Neck resistance 82 (64.1%) 65 (64.4%) 17 (63%) −0.134 0.894
 Pathological signs 25 (19.5%) 19 (18.8) 6 (22.2%) −0.396 0.692
CSF pressure (mmH2O)
  < 180 25 (19.5%) 23 (22.8%) 2 (7.4%) −1.741 0.082
 180–250 38 (29.7%) 30 (29.7%) 8 (29.6%)
  > 250 65 (50.8%) 48 (47.5%) 17 (63%)
CSF routine and biochemical
 WBC (cells/μl) 20 (10, 59) 20 (10, 61.5) 23 (10, 50) −0.138 0.891
 TP(g/L) 40.4 (30.8, 73.85) 38.6 (30.5, 64.9) 50.3 (30.9, 91) −1.256 0.209
 GLU (mmol/L) 2.45 ± 0.95 2.51 ± 0.89 2.24 ± 1.15 1.110 0.275
 CL (mmol/L) 117.9 ± 6.38 118.47 ± 5.78 115.76 ± 8.02 1.647 0.109
Etiological examination positive (cases)
 CSF Ink stain 105 (82%) 84 (83.2%) 21 (77.8%) −0.646 0.519
 CSF Cryptococcus antigen 128 (100%) 101 (100%) 27 (100%) 0.000 1.000
 CSF Cryptococcus culture 75 (58.6%) 59 (58.4%) 16 (59.3%) −0.079 0.937
 Blood Cryptococcus antigen 125 (97.7%) 99 (98%) 26 (96.3%) −0.524 0.600
 Blood Cryptococcus culture 67 (52.3%) 54 (53.5%) 13 (48.1%) −0.489 0.625
WBC(×109/L) 4.97 (3.37, 6.59) 4.94 (3.19, 6.82) 5.57 ± 2.04 −0.873 0.383
NE%(%) 78.26 (66.64, 83.26) 78.11 (65.8, 82.58) 76.63 ± 13.56 −1.171 0.242
LY%(%) 12.97 (7.92, 20.15) 12.92 (7.97, 20.85) 14.89 ± 11.1 −0.447 0.655
HGB(g/L) 120.04 ± 22.59 118.76 ± 22.47 124.80 ± 22.84 −1.237 0.218
PLT(×109/L) 175.5 (128.5, 226.25) 176 (117.5, 225.5) 166.50 ± 68.80 −0.517 0.605
ESR (mm/h) 41 (21.5, 66) 46.17 ± 27.77 27 (13, 68) −1.481 0.139
CRP (mg/L) 13.05 (4.58, 38.88) 14.7 (5.46, 47.6) 7.5 (3.6, 31) −1.273 0.203
PCT (ng/ml) 0.05 (0.05, 0.19) 0.06 (0.05, 0.21) 0.05 (0.05, 0.16) −0.489 0.625
K (mmol/L) 3.58 ± 0.53 3.62 ± 0.53 3.43 ± 0.55 1.613 0.109
Na (mmol/L) 131.98 ± 5.51 132.09 ± 5.28 131.59 ± 6.38 0.417 0.677
Cl (mmol/L) 97.23 ± 5.54 97.42 ± 5.26 96.51 ± 6.54 0.756 0.451
GLU (mmol/L) 6.33 (5.67, 7.46) 6.11 (5.54, 7.04) 6.91 (6.23, 8.1) −2.695 0.007
CD4(cells/μl) 22.5 (9.25, 47) 21 (9, 46) 26 (10, 55) −0.973 0.331
HIV RNA (copies/ml) 68,466.5 (18,675.5, 186,018.5) 84,218 (14,286, 182,126) 31,659 (19,412, 190,202) −1.072 0.284
Start/Unstart ART (cases) 32/96 25/76 7/20 0.016 0.901
Treatment timing/Course (weeks) 4 (3, 8) 4 (2, 8) 4 (3, 9) −0.672 0.502
Therapeutic schedule (cases)
 AmB ± 5FC 8 (6.3%) 7 (6.9%) 1 (3.7%) −1.825 0.068
 FLU±5FC 57 (44.5%) 47 (46.5%) 10 (37%)
 Voriconazole 4 (3.1%) 4 (4.0%) 0 (0%)
 Mixed regimens 39 (30.5%) 31 (30.7%) 8 (29.6%)
 Non-standard treatment 20 (15.6%) 12 (11.9%) 8 (29.6%)
Induction course (weeks) 5 (3, 10) 7 (4, 10) 2 (1, 5) −4.398 < 0.001
  1. Note: CSF Cerebrospinal fluid, WBC White blood cell, TP Total protein, GLU Glucose, CL Chloride ion, NE% Neutrophil%, LY% Lymphocyte, HGB Hemoglobin, PLT Platelet, ESR Erythrocyte sedimentation rate, CRP C reactive protein, PCT Procalcitonin, K Potassium ion, Na Sodium ion, CD4 CD4+ T lymphocyte count, ART Antiretroviral therapy, AmB ± 5FC Amphotericin B ± 5-fluorocytosine, FLU±5FC Fluconazole±5-fluorocytosine, Median (Q1, Q3) Median based on 25th and 75th percentiles